Harrow Q3 revenue up 44% to $49.3M; reaffirms FY2024 guidance above $180M

HARROW, INC.

2024-Q3 EPS reported -$0.68 revenue$132,783,000

GAAP net loss of $4.2M; Adjusted EBITDA $8.8M; core gross margin improved to 80%.
VEVYE prescriptions up 55% QoQ; IHEEZO unit demand up 15% QoQ; TRIESENCE relaunched in October.
Cash $72.6M; $37M milestone payment for TRIESENCE funded by $30M Oaktree drawdown.
First major Medicare Part D win for VEVYE with Express Scripts, Cigna, Kaiser, CVS Caremark.
FY2024 revenue guidance reaffirmed at >$180M; Q4 expected to significantly outpace Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.